Universal or targeted screening for fetal alcohol exposure: a cost-effectiveness analysis.
Very rarely therapeutic drug monitoring is evaluated for its ability to provide cost savings. A new article describes the cost-effectiveness of meconium analysis for fatty acid ethyl esters in the management of fetal alcohol spectrum disorder. This article is a summary and a critical appraisal of the article by Hopkins et al.
Zelner
Irene
I
Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Koren
Gideon
G
D003362:Cost-Benefit Analysis; D000431:Ethanol / Q000009:adverse effects; D005260:Female; D063647:Fetal Alcohol Spectrum Disorders / Q000175:diagnosis / Q000191:economics*; D006801:Humans; D007231:Infant, Newborn; D008403:Mass Screening / Q000191:economics*; D015997:Neonatal Screening / Q000191:economics*; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000175:diagnosis; D012307:Risk Factors
D000431:Ethanol